Roche Holding AG (ROG.SW)
| Previous Close | 269.60 |
| Open | 271.20 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 269.80 - 272.40 |
| 52 Week Range | 212.90 - 288.20 |
| Volume | |
| Avg. Volume | 1,270,507 |
| Market Cap | 218.875B |
| Beta (5Y Monthly) | 0.15 |
| PE Ratio (TTM) | 20.49 |
| EPS (TTM) | 13.24 |
| Earnings Date | Jul 25, 2024 |
| Forward Dividend & Yield | 9.60 (3.56%) |
| Ex-Dividend Date | Mar 14, 2024 |
| 1y Target Est | 269.74 |
ZacksRoche Wins FDA Nod for Breast Cancer Drug in First-Line Setting
RHHBY obtains FDA approval for Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.
GlobeNewswireMajority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate
Positive data confirm Evrysdi efficacy and safety in children first treated pre-symptomatically before six weeks of age, with most achieving motor milestones similar to children without SMAAll children were able to swallow and feed orally, with none requiring permanent ventilationEvrysdi is the only non-invasive SMA therapy and is approved in over 100 countries, with more than 16,000 people with SMA treated globally Basel, 14 October 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented positive t
Business WireMajority of Children With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Are Able to Sit, Stand and Walk Independently, Two-Year Data Demonstrate
SOUTH SAN FRANCISCO, Calif., October 14, 2024--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented positive 2-year data from the ongoing RAINBOWFISH study at the 29th World Muscle Society (WMS) Congress, October 8-12, 2024, assessing the efficacy and safety of Evrysdi® (risdiplam) in children with SMA who were treated pre-symptomatically as infants before 6 weeks of age (n=23). The study found the majority of children achieved key motor milestones, were able to swallow
